Immune response and endocytosis pathways are associated with the resilience against

2 Alzheimer's Disease 3 Niccolò Tesi 1,2,3, Sven J. van der Lee 1,2, Marc Hulsman 1,2,3, Iris E. Jansen 1,4, Najada Stringa 5,6, Natasja M. van Schoor 4 5,6, Philip Scheltens<sup>1</sup>, Wiesje M. van der Flier<sup>1,5</sup>, Martijn Huisman<sup>5,6</sup>, Marcel J. T. Reinders<sup>3</sup>, and Henne Holstege<sup>1,2,3</sup> 5 6 <sup>1</sup> Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam 7 UMC, Amsterdam, The Netherlands 8 <sup>2</sup> Department of Clinical Genetics, Amsterdam UMC, Amsterdam, The Netherlands 9 <sup>3</sup> *Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands* 10 <sup>4</sup> Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU 11 University, Amsterdam, the Netherlands 12 <sup>5</sup> Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, The Netherlands 13 <sup>6</sup> Amsterdam Public Health Research Institute, Amsterdam, The Netherlands 14 15 Keywords: centenarians, immune response, endosomal system, Alzheimer's disease, pathways, polygenic risk score, PRS, 16 longevity, resilience, cognitive health, etiology 17 18 Corresponding Author 19 Dr. Henne Holstege 20 Alzheimer's Center Amsterdam 21 Amsterdam UMC 22 De Boelelaan 1118 23 1081 HZ, Amsterdam, The Netherlands 24 Tel: +31 20 4440816 25 Email: h.holstege@amsterdamumc.nl

26

# Abstract

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Developing Alzheimer's disease (AD) is influenced by multiple genetic variants that are involved in five major ADpathways. Per individual, these pathways may differentially contribute to the modification of the AD-risk. The pathways involved in the resilience against AD have thus far been poorly addressed. Here, we investigated to what extent each molecular mechanism associates with (i) the increased risk of AD and (ii) the resilience against AD until extreme old age, by comparing pathway-specific polygenic risk scores (pathway-PRS). We used 29 genetic variants associated with AD to develop pathway-PRS for five major pathways involved in AD. We developed an integrative framework that allows multiple genes to associate with a variant, and multiple pathways to associate with a gene. We studied pathway-PRS in the Amsterdam Dementia Cohort of well-phenotyped AD patients (N=1,895), Dutch population controls from the Longitudinal Aging Study Amsterdam (N=1,654) and our unique 100-plus Study cohort of cognitively healthy centenarians who avoided AD (N=293). Last, we estimated the contribution of each pathway to the genetic risk of AD in the general population. All pathway-PRS significantly associated with increased AD-risk and (in the opposite direction) with resilience against AD (except for angiogenesis, p<0.05). The pathway that contributed most to the overall modulation of AD-risk was β-amyloid metabolism (29.6%), which was driven mainly by APOEvariants. After excluding APOE variants, all pathway-PRS associated with increased AD-risk (except for angiogenesis, p<0.05), while specifically *immune response* (p=0.003) and *endocytosis* (p=0.0003) associated with resilience against AD. Indeed, the variants in these latter two pathways became the main contributors to the overall modulation of genetic risk of AD (45.5% and 19.2%, respectively). The genetic variants associated with the resilience against AD indicate which pathways are involved with maintained cognitive functioning until extreme ages. Our work suggests that a favorable immune response and a maintained endocytosis pathway might be involved in general neuro-protection, which highlight the need to investigate these pathways, next to  $\beta$ -amyloid metabolism.

Introduction

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Due to changes in lifestyle and advances in healthcare, life expectancy has greatly increased during the last century.[1] A consequence of an increased fraction of aged individuals in the population is the increased prevalence of age-related diseases. A major contribution to poor health and disability at old age is cognitive decline due to Alzheimer's disease (AD).[2] The incidence of AD increases exponentially with age and reaches ~40% per year at 100 years, making it one of the most prevalent diseases in the elderly.[3] Yet, a small proportion of the population (<0.1%) avoids the disease, reaching at least 100 years while maintaining a high level of cognitive health.[4] Both the development and the resilience against AD are determined by a combination of beneficial and harmful environmental and genetic factors that is unique for each individual, [1, 5, 6] Thus far, large collaborative genome-wide association studies (GWAS) have discovered common genetic variants associated with a small modification of the risk of AD.[7–20] Of these, the alleles that encompass the APOE gene explain the largest proportion of the risk to develop or the chance to escape AD. We previously showed that those who avoided cognitive decline until extreme ages (cognitively healthy centenarians) were relatively depleted with genetic variants associated with an increased risk of AD.[21] However, the degree of depletion of these variants in the genomes of cognitively healthy centenarians relative to the middle-aged healthy individuals was not constant, which might point towards a differential impact of associated biological pathways on either avoiding or developing AD. This led us to hypothesize that an individuals' chance to develop AD or to being resilient against AD may be determined by pathway-specific risk. Previous studies indicated that five specific biological pathways associate strongly with AD risk: *immune response*,  $\beta$ -

Previous studies indicated that five specific biological pathways associate strongly with AD risk: immune response, js-amyloid metabolism, cholesterol/lipid dysfunction, endocytosis and angiogenesis.[22–27] However, the extent to which different pathways contribute to the polygenic risk of AD is unknown. The degree to which a pathway contributes to the individual risk can be studied with pathway-specific polygenic risk scores (PRS).[28, 29] In a typical polygenic risk score, the effect-sizes of all genetic variants that significantly associate with a trait are combined.[30] In a pathway-specific PRS, additional information is necessary: (i) the association of genetic variants to genes, and (ii) the association of genes to pathways. Previous studies of pathway-PRS in AD approached these challenges using the closest gene for variant mapping. For this, a 1:1 relationship between variants and genes is assumed, however, as AD-associated variants are mostly intronic or intergenic, the closest gene is not necessarily the gene affected by the variant. Additionally, different databases often have different functional annotations of genes, and this uncertainty was previously not taken into account when constructing pathway-PRS.[28, 29]

An accurate mapping of the genetic risk of AD conferred by specific molecular pathways may lead to a greater comprehension of individual AD subtypes and might represent a first important step for the development of targeted intervention strategies and personalized medicine.[31] Here, we propose a novel integrative framework to construct pathway-PRS for the five major pathways suggested to be involved in AD. We then tested whether specific pathways differentially contributed to the risk of AD as well as to the chance of avoiding AD until extreme old ages. Finally, we estimated the contribution of each pathway to the polygenic risk of AD in the general (healthy middle-aged) population.

### Methods

# **Populations**

Population subjects are denoted by *P*: they consist of a representative Dutch sample of 1,779 individuals aged 55-85 years from the Longitudinal Aging Study Amsterdam (LASA).[32, 33] Patients diagnosed with AD are denoted by *A*. The patients are either clinically diagnosed probable AD patients from the Amsterdam Dementia Cohort (N=1,630) or pathologically confirmed AD patients from the Netherlands Brain Bank (N=436).[34–36] Escapers of AD are denoted by *C*: these are 302 cognitively healthy centenarians from the 100-plus Study cohort. This study includes individuals who can provide official evidence for being aged 100 years or older and self-report to be cognitively healthy, which is confirmed by a proxy.[4] All participants and/or their legal representatives provided written informed consent for participation in clinical and genetic studies. The Medical Ethics Committee of the Amsterdam UMC (METC) approved all studies.

## Genotyping and imputation

We selected 29 common genetic variants (minor allele frequency >1%) for which a genome-wide significant association with clinically identified AD cases was found (*Table S1*).[7–18, 37–40] We genotyped all individuals using Illumina Global Screening Array (GSAsharedCUSTOM\_20018389\_A2) and applied established quality control measures.[41] Briefly, we used high-quality genotyping in all individuals (individual call rate >98%, variant call rate >98%) and Hardy–Weinberg equilibrium-departure was considered significant at *p*<1×10<sup>-6</sup>. Genotypes were prepared for imputation using provided scripts (HRC-1000G-check-bim.pl).[42] This script compares variant ID, strand and allele frequencies to the haplotype reference panel (HRC v1.1, April 2016).[35] Finally, all autosomal variants were submitted to the Michigan imputation server (https://imputa tionserver.sph.umich.edu). The server uses SHAPEIT2 (v2.r790) to phase data and imputation to the reference panel (v1.1) was performed with Minimac3. Variant-genotypes of total of 1,779 population subjects, 302 centenarians and 2,052 AD cases passed quality control. Prior to analysis, we excluded

individuals of non-European ancestry ( $N_C = 2$ ,  $N_P = 63$  and  $N_A = 94$  based on IoooGenomes clustering)[43] and individuals with a family relation ( $N_C = 7$ ,  $N_P = 62$  and  $N_A = 63$ , identity-by-descent >0.3), leaving I,654 population subjects, 293 cognitively healthy centenarians and I,895 AD cases for the analyses.

# Polygenic risk score

To calculate the personal polygenic risk scores, or the genetic risk of AD that affects a single individual, the effect-sizes of all genetic variants that significantly associate with AD are combined. Formally, a PRS is defined as the sum of trait-associated alleles carried by an individual across a defined set of genetic loci, weighted by effect-sizes estimated from a GWAS.[30] We constructed a polygenic risk score (PRS) using 29 variants that were previously associated with AD. As weights for the PRS, we used the variant effect-sizes (log of odds ratio) as published in large GWAS of AD (*Table St*). Given a subject *s*, the PRS is defined as:

$$PRS^{s} = \sum_{k}^{K} (dos_{k}^{s} * \beta_{k})$$
 (I)

where *K* is the full set of variants,  $dos_k^s$  is the allele dosage from the (imputed) genotype of variant *k* in subject *s* and  $\beta_k$  is the effect size as determined in the largest published AD case-control GWAS (*Table Si*).

### Mapping variants to pathways

- We studied the five pathways implicated in AD: *immune response*,  $\beta$ -amyloid metabolism, cholesterol/lipid dysfunction, endocytosis and angiogenesis.[22–25, 44, 45] For these pathways we developed the variant-pathway mapping  $M_p^k$ , which represents the degree of involvement of a given variant in the pre-selected pathways. To generate this value, we (i) associated genetic variants to genes (variant-gene mapping), (ii) associated genes to pathways (gene-pathway mapping) and (iii) combined these mappings in the variant-pathway mapping.
- *Variant-gene mapping:* the association of a variant with a specific gene is not straight-forward as the closest gene is not necessarily the gene affected by the variant. The two most recent and largest GWAS of AD addressed the relationship between genetic variants and associated genes applying two independent methods.[19, 20] Briefly, one study used (i) gene-based annotation, (ii) expression-quantitative trait loci (eQTL) analyses, (iii) gene cluster/pathway analyses, and (iv) differential gene expression analysis between AD cases and healthy controls.[19] The other study integrated (i) positional mapping, (ii) eQTL gene-mapping, and (iii) chromatin interaction as implemented in the tool Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA).[20, 46] The list of genes most likely affected by each variant was obtained from both studies and used to derive a weighted mapping for each genetic variant k to one or more genes g,  $m_{g}^{k}$ , denoted as the *variant-gene mapping* weight. This weight was calculated by counting the

number of times a variant k was associated with gene g across the two studies and dividing this by the total number of genes associated with the variant ( $Table\ S2$ ). For variants in/near CRI, PILRA, PLCG2, ABCA7 and APOE, we assumed the culprit gene as known, and we assigned a I:I relationship between the variant and the gene ( $Table\ S2$ ).

- *Gene-pathway mapping*: each gene from the *variant-gene mapping* was classified into the pre-defined set of pathways integrating four sources of information:
  - I. Gene-sets from the unsupervised pathway enrichment analysis within MAGMA statistical framework from *Kunkle et al.*,[19] in which the authors identified 9 significant pathways (coupled with the genes involved in each pathway), which we mapped to 3 of the 5 pathways of interest (*Table S3*);
  - 2. Associated genes from Gene-ontology (GO, from *AmiGO 2* version 2.5.12, released on 2018-04) terms resembling the 5 pathways of interest within the biological processes tree (including all child-terms) (*Table S4*);[47, 48]
  - 3. Gene-sets derived from an unsupervised functional clustering analysis within DAVID (v6.8, released on 2016-10):[49, 50] the gene-set from the *variant-gene mapping* was used to obtain 12 functional clusters which were then mapped to the 5 pre-selected pathways using a set of keywords (*Table S5* and *Table S6*);
- 4. Gene-pathway associations from a recent review concerning the genetic landscape of AD ( $Table\ S7$ );[22] By counting the number of times each gene was associated to each pathway according to these sources, and dividing by the total number of associations per gene, we obtained a weighted mapping of each gene g to one or more pathways p,  $w_p^g$ , denoted as the gene-pathway mapping weight ( $Table\ S8$  and  $Table\ S9$ ). In case the gene-pathway mapping could not be calculated (i.e there was no mapping to any of the pathways of consideration), we excluded the gene from further analyses ( $Table\ S8$  and  $Table\ S9$ ).
- To associate variants with pathways, we combined the *variant-gene mapping* and the *gene-pathway mapping*. Given a variant k, mapping to a set of genes G, and a pathway p, we define the weight of the variant to the pathway  $(M_p^k)$  as:

166 
$$M_p^k = \sum_{g}^{G} (m_g^k * w_p^g)$$
 (2)

where  $m_g^k$  is the *variant-gene mapping* weight of variant k to gene g, and  $w_p^g$  is the *gene-pathway mapping* weight of gene g to pathway p. In this way, for each variant, we calculated a score indicative of the involvement of the variant in each of the five pathways (*variant-pathway mapping*, *Table S10*). For some variants no *variant-pathway mapping* was possible. We marked these variants as unmapped (*Table S10*).

# Pathway-specific polygenic risk score

For the pathway-specific polygenic risk score (pPRS), we extended the definition of the PRS by adding as multiplicative factor the *variant-pathway mapping* weight of each variant. Given a sample *s* and a pathway *p*, we defined the pPRS as:

$$pPRS_p^s = \sum_{k}^{K} (dos_k^s * \beta_k * M_k^p)$$
(3)

where  $M_k^p$  is the *variant-pathway mapping* of variant k to pathway p.

### Association of PRSs in the three cohorts

We calculated the polygenic risk score (PRS) and pathway-PRS (pPRS) for the population subjects, the AD cases and the cognitively healthy centenarians (*P*, A and *C*, respectively). Prior to analyses, the PRSs of all three populations were combined together and were scaled (mean=0, SD=1). We then investigated the influence of *APOE*, gender and age on the risk scores: we calculated the PRSs and pPRSs with and without the two *APOE* variants and we correlated the resulting (p)PRSs with sex, age (age at inclusion for controls, age at onset for cases) and population substructure components. To inspect the differential contributions of the risk scores to AD development or resilience against AD, we calculated (*i*) the association of the risk scores (PRS and pPRS) with AD status by comparing AD cases and population subjects (*A vs. P*), and (*ii*) the association of the risk scores with resilience against AD by comparing cognitively healthy centenarians and population subjects (*C vs. P* comparison). For the associations, we used logistic regression models with the PRS and pPRS as predictors, adjusting for population substructure (principal components 1-5). Resulting effect-sizes (log of odds ratio) can be interpreted as the odds ratio difference per one standard deviation (SD) increase in the PRS, with a corresponding estimated 95% confidence intervals (95% CI). Association analyses of the (p)PRS in the three population were also stratified by sex. Last, we verified the classification performances of the single variants as well as the (p)PRS by calculating the area under the ROC curve for classification of AD and resilience against AD.

# Comparison of effect-size between resilience against AD and increased AD-risk

To further investigate the relationship between the effect of each pathway on AD and on resilience against AD, we calculated the *change* in effect-size. This corresponds to the ratio between the effect-size of the association with resilience against AD (log of odds ratios of *C vs. P* comparison) and the effect-size of the association with AD (log of odds ratios of *A vs. P* comparison). We calculated the *change* in effect-size for the pPRS including and excluding *APOE* variants. We estimated 95% confidence intervals for the effect-size ratios by sampling, and we tested for significant difference between the *change* in effect-size including and excluding *APOE* variants (respectively for each of pPRS) using t-test. A value for the *change* in effect-size of I indicates a similar effect on increased risk of AD and resilience

against AD. Although a value for the *change* in effect size unknown *a priori*, since all variants considered are selected to be associated with AD, a value <1 is expected (*i.e* a larger effect on AD than on resilience against AD).

# Contribution of each pathway to polygenic risk of AD

We estimated the contribution of each pathway to the genetic risk of AD in the general population: this equals to the variance explained by each of the pre-selected pathways to the genetic risk of AD. Mathematically, this is the ratio between the variance of each pathway-PRS and the variance of the combined PRS as calculated in the individuals in the general population. As such, it is a function of the *variant-pathway mapping*, the effect-size (log of odds ratio) of the variants, and the variant frequencies. Given a variant k and the relative *variant-pathway mapping*  $M_k^p$ , we define the percentage of the risk explained by each pathway p as:

$$P^{p} = \frac{\sum_{k}^{K} (M_{k}^{p} * \beta_{k}^{2} * MAF_{k} * (1 - MAF_{k}))}{\sum_{k}^{K} (\beta_{k}^{2} * MAF_{k} * (1 - MAF_{k}))}$$
(4)

where  $\beta_k$  is the variant effect-size from literature, and  $MAF_k*(1-MAF_k)$  is the variance of a Bernoulli random variable that occurs with probability  $MAF_k$ , *i.e* the minor allele frequency of each variant k in our cohort of population subjects. Here,  $M_k^p$  is interpreted as the probability that variant k belongs to pathway p. Importantly, for each variant,  $\sum_{p}^{p} M_k^p = 1$ , so that each variant contributes equally, yet differentially at the level of each pathway. This means that the variance of a variant is only counted once, even if the variant contributes to multiple pathways. When calculating the contributions of each pathway, we also considered variants with missing *variant-pathway mapping*. For these variants, the *variant-pathway mapping* was set to I for an *unmapped* pathway. Together, the pathway PRS variances sum to the total PRS variance.

## **Implementation**

We performed quality control of genotype data as well as population stratification analysis and relatedness analysis with PLINK (v2.o). All subsequent analyses were performed with R (v3.5.2), Bash and Python (v2.7.14) scripts. We provide a R script to construct pPRS and PRS using our *variant-pathway annotation* and user's genotypes. In addition, all the scripts we used to perform the analyses can be found at <a href="https://github.com/TesiNicco/pathway-PRS">https://github.com/TesiNicco/pathway-PRS</a>.

# Results

After quality control of the genetic data, we included 1,654 population subjects (with mean age at inclusion 62.7±6.4, 53.2% females), 1,895 AD cases (with mean age at onset 69.2±9.9, 56.4% females), and 293 cognitively healthy centenarians (with mean age at inclusion 101.4±1.3, 72.6% females) (*P*, *A* and C respectively).

Polygenic risk scores associate with AD and escape from AD To each subject, we assigned a PRS representative of all 29 AD-associated variants, including and excluding APOE variants. We found that the PRS, when including APOE variants, significantly associated with an increased risk of AD and, in the opposite direction, with increased chance of resilience against AD (A vs. P: OR=2.61, 95% CI=[2.40-2.83], p=8.4x10<sup>-113</sup> and C vs. P: OR=0.54, 95% CI=[0.45-0.65], p=1.1x10<sup>-10</sup>) (Figure 1A and Table S11). When excluding APOE variants, the PRS was still significantly associated with an increased risk of AD and, in the opposite direction, with increased risk of resilience against AD (A vs. P: OR=1.30, 95% CI=[1.22-1.40], p=3.1x10<sup>-14</sup> and C vs. P: OR=0.78, 95% CI=[0.69-1.20] 0.89],  $p=2.4\times10^{-4}$ ) (*Figure 1B*, and *Table S11*). Pathway-specific PRS associate with AD and escape from AD We annotated the 29 AD-associated genetic variants to 5 selected pathways (Figure 2). According to our variant-gene mapping, the 29 AD-associated variants mapped to IIO genes (Table S8). The number of genes associated with each variant ranged from I (e.g. for variants in/near CRI, PILRA, SORLI, ABCA7, APOE or PLCG2), to 30 (a variant in the genedense region within the HLA region) (Figure 2 and Table S8). We were able to calculate the gene-pathway mapping weight for 69 genes (Table S9). The remaining 41 genes were not mapped to the 5 pathways. In total, we calculated the variant-pathway mapping for 23 loci to at least one of the pre-selected biological pathways (Figure 2 and Table S10). We then calculated the pPRS for each pathway in population subjects, AD cases and cognitively healthy centenarians including and excluding APOE variants (Figure 1B and IC). The number of variants that contributed to each pPRS was 19 for immune response, 11 for β-amyloid metabolism, 19 for endocytosis, 8 for cholesterol/lipid dysfunction and 4 for angiogenesis pathways (Table SIO and Table SII). Overall, the pPRS (including and excluding the APOE variants) positively and significantly correlated with each other and with the overall PRS (Figure S1), and did not correlate with gender and age (Figure S1). When including APOE variants, the pPRSs of all pathways (except for angiogenesis) significantly associated with increased risk of AD, independently from gender (A vs. P, immune response: OR=2.15, 95% CI=[1.99-2.32], p=2.0x10<sup>-80</sup>; βamyloid metabolism: OR=2.52, 95% CI=[2.32-2.73],  $p=7.8\times10^{-109}$ ; endocytosis: OR=2.55, 95% CI=[2.35-2.77],  $p=1.7\times10^{-109}$ ; cholesterol/lipid dysfunction: OR=2.55, 95% CI=[2.35-2.76], p=2.IXIO<sup>-110</sup>; angiogenesis: OR=1.05, 95% CI=[0.98-1.12], p=0.134) (Figure 1B, Table S11, Figure S2 and Table S12). The association of pPRSs with increased chance of being resilient against AD was in the opposite direction for all pathways, and the association was significant for all pathways except for

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

angiogenesis (C vs. P, immune response: OR=0.64, 95% CI=[0.54-0.74],  $p=1.4\times10^{-8}$ ;  $\beta$ -amyloid metabolism: OR=0.59, 95%  $CI=[0.49-0.71], p=2.7x10^{-8}; endocytosis: OR=0.55, 95\% CI=[0.46-0.66], p=1.3x10^{-10}; cholesterol/lipid dysfunction: OR=0.58, 95\% CI=[0.49-0.71], p=2.7x10^{-8}; endocytosis: OR=0.58, 95\% CI=[0.49-0.71], p=2.7x10^{-10}; cholesterol/lipid dysfunction: OR=0.58, 95\% CI=[0.40, 0.40, 0.40], p=2.7x10^{-10}; cholesterol/lipid dysfunction: OR=0.7x10^{-10}; cholesterol/lipid d$ CI=[0.48-0.70],  $p=1.8\times10^{-8}$ ; angiogenesis: OR=0.90, 95% CI=[0.79-1.01], p=0.078) (Figure 1B, Table S11). Directions of effects were consistent in both males and females, but the significance of associations was reduced due to stratification (Table S12 and Figure S2). When excluding APOE variants, the pPRSs of all pathways (except for the angiogenesis) was still significantly associated with increased risk of AD without specific gender effects (A vs. P, immune response: OR=1.19, 95% CI=[1.11-1.27], p=5.5x10 <sup>7</sup>; β-amyloid metabolism: OR=1.19, 95% CI=[1.12-1.28], p=2.0x10<sup>-7</sup>; endocytosis: OR=1.27, 95% CI=[1.19-1.36], p=2.8x10<sup>-12</sup>; cholesterol/lipid dysfunction: OR=1.18, 95% CI=[1.11-1.27], p=7.5x10<sup>-7</sup>; angiogenesis: OR=1.05, 95% CI=[0.98-1.12], p=0.134) (Figure 1C, Table S11, Figure S2 and Table S12). The association of pPRSs with increased chance of being resilient against AD was in the opposite direction for all pathways, yet the association was significant only for the immune response and the endocytosis pPRS (C vs. P, immune response: OR=0.82, 95% CI=[0.72-0.94], p=0.003; \(\beta\)-amyloid metabolism: OR=0.91, 95% CI=[0.80-1.03], p=0.131; endocytosis: OR=0.79, 95% CI=[0.70-0.90], p=2.8x10<sup>-4</sup>; cholesterol/lipid dysfunction: OR=0.91, 95% CI=[0.80-1.03], *p*=0.145; *angiogenesis*: *OR*=0.90, 95% CI=[0.79-1.01], *p*=0.078) (*Figure 1C* and *Table S11*). In the sex-stratified analysis, females reported consistent direction of effects and significant associations of immune response and endocytosis pathways, while in males the direction was consistent for immune response, endocytosis and angiogenesis pathways, and it was opposite for  $\beta$ -amyloid metabolism and cholesterol/lipid dysfunction (yet not significant) (Figure S2 and Table S12). We note that apart from APOE variants (for which we stratified the analyses for), there was no major driver in the pPRS as well as the single-variant associations (*Figure S*<sub>3</sub> and *Figure S*<sub>4</sub>). Comparison of effect on AD and escaping AD To further evaluate the association of the pPRSs with AD and with resilience against AD, we compared, for each pPRS, the reciprocal effect size associated with resilience against AD with the effect size associated with increased risk of AD (change in effect size, Figure 3A). When including APOE variants, the change in effect-size was <1 for all pathways (except for the angiogenesis pathway) (Figure 3B). This is expected as the effect-size of APOE variants on causing AD is much larger than its effect on resilience against AD (Figure 3A). When excluding APOE variants, the change in effect-size was still <I for  $\beta$ -amyloid metabolism and cholesterol/lipid metabolism (respectively 0.54 and 0.58), but it approximated I for endocytosis (0.96) and it was larger than I for the immune response and angiogenesis (respectively I.I2 and 2.15) (Figure 3B). Interestingly, we found that the relative effect-size for immune response and endocytosis excluding APOE variants was

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

significantly higher than that including APOE variants (p<2.1XIO<sup>-197</sup> and p<8.9XIO<sup>-180</sup> respectively), suggesting a larger effect on resilience against AD compared to AD-risk for these pathways, specifically when excluding APOE variants (*Figure 3B*).

# Contributions of each pathway to the polygenic risk of AD

Finally, we estimated the relative contribution of each pathway to the polygenic risk of AD in the general population.

This is indicative of the degree of involvement of each pathway to the total polygenic risk of AD, and as such it is based

on out variant-pathway mapping. Including APOE variants, the contribution of the pathways to the total polygenic risk

of AD was 29.6% for β-amyloid metabolism, 26.6% for immune response, 21.6% for endocytosis, 19.5% for cholesterol/lipid

dysfunction, 0.3% for angiogenesis and 2.3% for the unmapped variants (Figure 4A).

When we excluded APOE variants, the contribution of the pathways to the total polygenic risk of AD was 45.5% for

immune response, 19.2% for endocytosis, 13.7% for β-amyloid metabolism, 8% for cholesterol/lipid dysfunction, 1.4% for

In this work, we studied 29 common genetic variants known to associate with AD using polygenic risk scores and

angiogenesis and 12.3% for the unmapped variants (*Figure 4B*).

## Discussion

pathway-specific polygenic risk scores. As expected, we found that a higher PRS for AD was associated with a higher risk of AD. Previous studies showed that polygenic risk score of AD not only associated with increased risk of AD, but also with neuropathological hallmarks of AD, lifetime risk and the age at onset in both  $APOE \ \epsilon 4$  carriers and non-carriers. [28, 29, 51–55] We now add that, using our unique cohort of cognitively healthy centenarians, the PRS for AD also associates with resilience against AD at extremely old ages. This adds further importance to the potentiality of using PRS and APOE genotype in a clinical setting. [51, 52, 54, 56] In addition, our analyses suggest that the long-term preservation of cognitive health is associated with the selective survival of individuals with the lowest burden of risk-increasing variants or, vice versa, the highest burden of protective variants.

Using an innovative approach, we studied five pathways previously found to be involved in AD as well as the contribution of these pathways to the polygenic risk of AD. We showed that all pathways-PRS except *angiogenesis* associate with increased AD risk, both including and excluding APOE variants and independently from gender. When we studied the association of pathways-PRS with resilience against AD until extreme old ages, we found that, as expected, the enrichment of the protective APOE  $\epsilon 2$  allele and the depletion of the risk-increasing APOE  $\epsilon 4$  allele represented a major factor in avoiding AD. However, when excluding the two APOE variants, only *immune response* and *endocytosis* significantly associated with an increased chance to be resilient against AD. Interestingly, both

pathways had a larger or similar effect on resilience against AD-resilience compared to developing AD, suggesting that these pathways might be involved in general neuro-protective functions. Based on the variant effect size, variant frequency and our variant-pathway mapping, we found that the β-amyloid metabolism (29.6%) followed by immune response (26.6%) were the major contributors to general modification of AD-risk. After excluding APOE variants, according to our analysis, immune response (45.5%) and endocytosis (19.2%) contributed most to the modification of ADrisk. Our approach to map variants to associated genes and to map genes to pathways resulted in a weighted annotation of variants to pathways that allowed for uncertainty in gene as well as pathway assignment, which was not done previously. We note that considering uncertainty in variant-gene as well as gene-pathway assignments is crucial because most genetic variants are in non-coding regions, which makes the closest gene not necessarily the culprit gene, and because different functional annotation-sources often do not overlap. In our variant-pathway mapping, a larger number of annotations (both variant-genes and gene-pathways), generally causes a dilution of the "true" variant effect, reflecting increasing uncertainty in the annotation sources used. This depends on the specific regions, for example, the HLA region carries many genes with large linkage signals, however, all genes in this region are typically annotated with immune response. We point out that the power of the PRSs does not only reflect the effect-size of the variants, but also the number and frequency of the variants that contribute to the PRSs: due to this, a larger number of very common variants with relatively small effect-size can still have more power (yet small ORs) than a small number of relatively rare variants with high effect-size. The pathway-specific PRS that we proposed in this manuscript can be re-used for the identification of subtypes of AD patients compromised in a specific AD-associated pathway. This is of interest for clinical trials, in order to test responsiveness to compounds in specific subsets of patients. For example, monoclonal antibody targeting TREM2 receptors could work better in AD patients who have an impaired immune response pathway. Recently, several studies attempted to construct pathway-specific PRS to find heterogeneity in AD patients based on a genetic basis. [28, 29] In line with our findings, Ahmad et al. found that genes capturing endocytosis pathway significantly associated with AD and with the conversion to AD.[29] Other studies used less variants [28] or less stringent selection for variants, and did not observe a differential involvement of pathways in AD etiology.[57] The amyloid cascade hypothesis has been dominating AD-related research in the last two decades. However, treatments targeting amyloid have, so far, not been able to slow or stop disease progression. This has led to an increased interest for the other pathways that are important in AD pathogenesis.[22] Part of the current view of the etiology of AD is that the dysregulation of the immune response is a major causal pathway, and that AD is not only a

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

consequence of β-amyloid metabolism.[58, 59] In addition, previous studies showed that healthy immune and metabolic systems are associated with longer and healthier lifespan.[I, 60] Our results indicate that, excluding APOE variants, the effect of immune response and endocytosis on escaping AD is stronger or comparable to the effect on causing AD. This suggests that these pathways might be involved in the maintenance of general cognitive health, as the cognitively healthy centenarians represent the escape of all neurodegenerative diseases until extreme ages. We recently found evidence for this hypothesis in the protective low frequency variant in PLCG2, which is involved in the regulation of the immune response.[53] This variant is enriched in cognitively healthy centenarians, and protects against AD as well as frontotemporal dementia and dementia with Lewy bodies.[53] We included this variant in the total PRS as well as in the pathway-PRS for the immune response (variant-pathway mapping was 60%) and endocytosis (variant-pathway mapping was 40%). Regarding endocytosis, this pathway is thought to play a role both in neurons, as part of the β-amyloid metabolism, but also in glia cells, as part of the immune response. Thus, a dysregulation in the interplay between these pathways might lead to an imbalance of immune signaling factors, favoring the engulfment of synapses and AD-associated processes. This, in turn, may contribute to the accumulation of amyloid and tau pathologies.[61-64]. We assessed the effect of common and low frequency variants on the development and the escape of AD. Therefore, the contributions of rare, causative variants associated with increased AD risk, such as those in APP, PSENI, PSEN2, TREM2 and SORLI were not considered. Despite the large odds ratios to develop AD associated with carrying such variants, the frequency of these variants in the population is ultra-low, and therefore have a minor effect on the total AD risk in the population.[II, 12] However, future versions of the PRS will most likely include the effect of carrying disease-associated rare variants. This will affect individual PRS scores and the necessity to accordingly adapt the results generated with current PRSs. Compared to the sizes of recent GWAS of AD, we included relatively small sample sizes, particularly with respect to the cognitively healthy centenarians, a very rare phenotype in the population (<0.1%),[4] These sample sizes are however sufficient to study PRSs. The cohorts that we used in this study were not used in any GWAS of AD, therefore we provide independent replication of AD PRS in a homogeneous group of (Dutch) individuals. We note that, apart from APOE variants (for which we stratify the analyses for), none of the other variants have been associated with longevity or well cognitive functioning in the largest and most recent GWAS.[65, 66] We acknowledge that our variant-pathway mapping reflects the current state of imperfect knowledge at the level of AD-GWAS findings, variant-gene and gene-mechanism relationships. Thus, as new variants, pathways or functional relationships will be identified, the contributions and the pathway-specific PRSs will need to be recalculated. Of note: the study in which

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

the genome-wide significant association with AD of the variant in/near KANSLI was originally identified, reported a larger effect size compared to the effect size used in our manuscript, ( $\beta$ =0.31 and  $\beta$ =0.07, respectively), possibly because the original analysis was stratified by APOE. We cannot exclude that we underestimated the contribution of KANSLI in the analyses. Moreover, since the KANSLI variant did not map into one of the analyzed pathways, it was not included in any of the pathway-specific PRS calculations. A limitation, not exclusive to our work, is the highly debated role of APOE gene. We mapped the effect of APOE to four pathways and we are aware this assignment is relatively arbitrary. We add that APOE has well-studied (cardio)vascular properties that are included in our cholesterol and lipid metabolism pathway. The combination of a large effect and unclear pathway assignment makes that pathway-PRS including APOE challenging to use. Lastly, we point out that the variance contributions might change in different populations, as it depends on variant frequency and population heterogeneity.

Concluding, with the exclusion of *APOE* variants and based on our functional annotation of variants, the aggregate contribution of the immune response and endocytosis represents more than 60% of the currently known polygenic risk of AD. This indicates that an intervention in these systems may have large potential to prevent AD and potentially other related diseases and highlights the critical need to study (neuro)immune response and endocytosis, next to  $\beta$ -amyloid metabolism.

# Acknowledgements

The following studies and consortia have contributed to this manuscript. Amsterdam dementia cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience (www.amsterdamresearch.org). The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stiching VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). 100-plus study: we are grateful for the collaborative efforts of all participating centenarians and their family members and/or relatives. This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Dioraphte, horstingstuit foundation, Memorabel (ZonMW projectnumber 733050814) and Stichting VUmc Fonds. Genotyping of the 100-plus study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). The clinical database structure was developed with funding from Stichting Dioraphte. Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care. The authors are grateful to all LASA

422 participants, the fieldwork team and all researchers for their ongoing commitment to the study. This work was in part

carried out on the Dutch national e-infrastructure with the support of SURF Cooperative. The authors declare no

424 conflict of interests.

423

#### References

- 427 I. Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. Nature. 2018;561:45–56.
- 428 2. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8:131–168.
- 429 3. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age
- in the oldest old: The 90+ study. Ann Neurol. 2010;67:114–121.
- 431 4. Holstege H et al. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. Eur J
- 432 Epidemiol. 2018. 25 October 2018. https://doi.org/10.1007/s10654-018-0451-3.
- 433 5. Niccoli T, Partridge L. Ageing as a Risk Factor for Disease. Curr Biol. 2012;22:R741–R752.
- 434 6. Brooks-Wilson AR. Genetics of healthy aging and longevity. Hum Genet. 2013;132:1323–1338.
- $435 \hspace{10mm} \textbf{7.} \hspace{10mm} \textbf{Lambert JC et al. Meta-analysis of 74,046 individuals identifies II new susceptibility loci for Alzheimer's disease. Nat}$
- 436 Genet. 2013;45:1452–1458.
- 437 8. Harold D et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's
- 438 disease. Nat Genet. 2009;41:1088–1093.
- 9. Seshadri S et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832–1840.
- 440 IO. Desikan RS et al. Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. Circulation.
- 441 2015;131:2061-2069.
- 442 II. Sims R et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in
- 443 Alzheimer's disease. Nat Genet. 2017;49:1373–1384.
- 444 I2. Guerreiro R et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117–127.
- Jonsson T et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107–116.
- 446 14. Hollingworth P et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with
- 447 Alzheimer's disease. Nat Genet. 2011;43:429–435.
- Naj AC et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset
- 449 Alzheimer's disease. Nat Genet. 2011;43:436–441.
- 450 I6. Jun G et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016;21:108–117.
- 451 17. Steinberg S et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nat Genet. 2015;47:445–447.
- 452 18. Marioni R et al. GWAS on family history of Alzheimer's disease. 2018.
- 453 19. Alzheimer Disease Genetics Consortium (ADGC), et al. Genetic meta-analysis of diagnosed Alzheimer's disease
- 454 identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51:414–430.
- Jansen IE et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's
- 456 disease risk. Nat Genet. 2019;51:404–413.
- Tesi N et al. Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme
- 458 control analysis of Alzheimer's disease. Eur J Hum Genet. 2018. 26 September 2018. https://doi.org/10.1038/s41431-018-0273-5.
- 459 Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical
- implications and perspectives. Genet Med. 2016;18:421–430.
- 461 23. Hardy J et al. Pathways to Alzheimer's disease. J Intern Med. 2014;275:296–303.
- 462 24. Naj AC, Schellenberg GD, for the Alzheimer's Disease Genetics Consortium (ADGC). Genomic variants, genes, and
- pathways of Alzheimer's disease: An overview. Am J Med Genet B Neuropsychiatr Genet. 2017;174:5–26.
- 464 25. Verheijen J, Sleegers K. Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics.
- 465 Trends Genet. 2018;34:434–447.
- 466 26. Bennett RE et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic
- mice and human Alzheimer's disease. Proc Natl Acad Sci. 2018;115:E1289–E1298.
- 468 27. Di Marco LY et al. Vascular dysfunction in the pathogenesis of Alzheimer's disease A review of endothelium-
- mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015;82:593–606.
- 470 28. Darst BF et al. Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function
- 471 in a Sample at Increased Risk for Alzheimer's Disease. J Alzheimers Dis. 2016;55:473-484.

- 472 29. Ahmad S et al. Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam
- 473 Study. Alzheimers Dement. 2018;14:848–857.
- 474 30. Dudbridge F. Power and Predictive Accuracy of Polygenic Risk Scores. PLoS Genet. 2013;9:e1003348.
- 475 3I. Freudenberg-Hua Y, Li W, Davies P. The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A
- Narrative Review. Front Med. 2018;5:108.
- 477 32. Huisman M et al. Cohort Profile: The Longitudinal Aging Study Amsterdam. Int J Epidemiol. 2011;40:868–876.
- 478 33. Hoogendijk EO et al. The Longitudinal Aging Study Amsterdam: cohort update 2016 and major findings. Eur J
- 479 Epidemiol. 2016;31:927–945.
- 480 34. van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis.
- 481 2018;62:1091-1111.
- 482 35. van der Flier WM et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis JAD.
- 483 2014;41:313-327.
- 484 36. Rademaker MC, de Lange GM, Palmen SJMC. The Netherlands Brain Bank for Psychiatry. Handb. Clin. Neurol., vol.
- 485 150, Elsevier; 2018. p. 3–16.
- 486 37. Lambert J-C et al. Genome-wide association study identifies variants at CLU and CRI associated with Alzheimer's
- 487 disease. Nat Genet. 2009;41:1094–1099.
- 488 38. Strittmatter WJ et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in
- late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977–1981.
- 490 39. Corder EH et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet.
- 491 1994;7:180-184.
- 492 40. Jansen I et al. Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimers disease risk. 2018.
- 493 41. Das S et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48:1284–1287.
- 494 42. McCarthy S et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48:1279–1283.
- 495 43. 1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature. 2015;526:68–74.
- 496 44. Jefferies WA et al. Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease. Alzheimers
- 497 Res Ther. 2013;5:64.
- 498 45. Vagnucci AH, Li WW. Alzheimer's disease and angiogenesis. The Lancet. 2003;361:605–608.
- Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations
- with FUMA. Nat Commun. 2017;8.
- Ashburner M et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet.
- 502 2000;25:25-29.
- The Gene Ontology Consortium. Expansion of the Gene Ontology knowledgebase and resources. Nucleic Acids Res.
- 504 2017;45:D331-D338.
- Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID
- bioinformatics resources. Nat Protoc. 2009;4:44–57.
- 50. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional
- analysis of large gene lists. Nucleic Acids Res. 2009;37:I–13.
- 509 51. Escott-Price V, Myers AJ, Huentelman M, Hardy J. Polygenic risk score analysis of pathologically confirmed Alzheimer
- disease: PRS Analysis of AD. Ann Neurol. 2017;82:311–314.
- 511 52. Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction captures nearly all common genetic
- risk for Alzheimer's disease. Neurobiol Aging. 2017;49:214.e7-214.e11.
- 513 53. DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank) et al. A
- 514 nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal
- dementia, and increases the likelihood of longevity. Acta Neuropathol (Berl). 2019. 27 May 2019. https://doi.org/10.1007/s00401-019-
- 516 02026-8.
- for the International Genomics of Alzheimer's Project et al. Evaluation of a Genetic Risk Score to Improve Risk

- Prediction for Alzheimer's Disease. J Alzheimers Dis. 2016;53:921–932.
- 519 55. Chaudhury S et al. Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive
- 520 impairment. Transl Psychiatry. 2019;9.
- 521 56. van der Lee SJ et al. The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and
- dementia: a community-based cohort study. Lancet Neurol. 2018;17:434–444.
- 523 57. Leonenko G et al. Genetic risk for Alzheimer's disease is distinct from genetic risk for amyloid deposition. Ann Neurol.
- 524 2019. 14 June 2019. https://doi.org/10.1002/ana.25530.
- 525 58. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777–783.
- 526 59. Heneka MT et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14:388–405.
- 527 60. Joshi PK et al. Genome-wide meta-analysis associates HLA-DQAI/DRBI and LPA and lifestyle factors with human
- 528 longevity. Nat Commun. 2017;8.
- 529 61. Srinivasan K et al. Untangling the brain's neuroinflammatory and neurodegenerative transcriptional responses. Nat
- 530 Commun. 2016;7.
- Wang Y et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med.
- 532 2016;213:667-675.
- Orre M et al. Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction. Neurobiol Aging.
- 534 2014;35:2746-2760.

- 535 64. Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217:459–472.
- Timmers PR et al. Genomics of I million parent lifespans implicates novel pathways and common diseases and
- distinguishes survival chances. ELife. 2019;8.
- Davies G et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive
- function. Nat Commun. 2018;9.




Figure I: Boxplots of PRS and pPRS in the different settings. Figure A (above) shows the PRS including all the 29 known AD-associated variants, with and without *APOE* variants. As weight for the PRS, we used published variant effect-sizes (*Table SI*). Figure B (central) and Figure C (bottom) show the pPRS for each of the selected molecular pathways, including and excluding *APOE* variants, respectively. For all plots, risk scores were calculated for AD cases, population subjects and cognitively healthy centenarians. Then, risk scores were compared between (*i*) AD cases and population subjects (*A vs. P* comparison) and (*ii*) cognitively healthy centenarians and population subjects (*C vs. P* comparison). For representation, we scaled all PRS and pathway-PRS to be mean=0 and SD=I. For the comparison, we used logistic regression models with risk scores as predictors. Annotation: \*\*\*, *p-value* of association < 5x10<sup>-6</sup>; \*\*, *p-value* of association < 5x10<sup>-2</sup>.




Figure 2: Variant-pathways mapping: Locus: chromosome and position of the AD-associated genetic variants (coordinates are with respect to GRCh37). N. genes: total number of genes associated with each variant according to variant-gene mapping. Variant-gene mapping: Genes: all genes with at least one annotation to the 5 selected molecular pathways associated with AD. Weight: the weight of the variant-gene mapping. Gene-pathway mapping: Immune response, Beta-amyloid, Endocytosis, Cholesterol/lipid, Angiogenesis: the weight of each molecular pathway at the gene level. Variant-pathway mapping: summarization of each variant's effect after combining variant-gene and gene-pathway mappings. Red crosses indicate unmapped genes.





Figure 3: *Change* in effect-size between association with escaping AD and causing AD for the five pPRSs: figure A shows the effect-sizes (log of odds ratio) and the relative 95% confidence intervals of the association of the (p)PRS with both AD-risk and resilience against AD, grouped by pathway. In figure B, each bar represents the ratio between the effect-size of the association with escaping AD (*Resilience effect* in figure A) and with causing AD (*Risk effect* in figure A), respectively with and without *APOE* variants. Ratios larger than I are then indicative of larger effect-size on resilience against AD compared to AD-risk. We then compared the *change* in effect-size for each pathway when including and excluding *APOE* variants using t-tests. Annotation: \*\*\*, *p-value* of association < 5xIO<sup>-6</sup>; \*\*, *p-value* of association < 5xIO<sup>-6</sup>;

# **APOE** included

# **APOE** excluded






Figure 4: Explained variance of each pathway-specific PRS to polygenic risk of AD: the pie charts represents the explained variance of each pathway-specific PRS to the polygenic risk of AD, including and excluding *APOE* variants. The contributions are calculated according to (*i*) our *variant-pathway mapping*, (*ii*) the effect size (log of odds ratio) of each variant from literature (*Table Si*), and (*iii*) variant's frequency in our cohort of middle-aged healthy population subjects. We also considered variants with missing *variant-pathway mapping* (*unmapped* pathway).